Just reported
Q3 2026 results
From Castle Biosciences, Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Revenue
Actual
$102.9M
+24% y/y ↑
-0.6% q/q ↓
EPS, GAAP
Operating income, GAAP
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|
| Total Revenue | $102.9M | $83M | +23.90% |
| Profit | -$4.1M | -$501K | -718.36% |
| Profit per share | -$0.13 | -$0.02 | -550.00% |
| Free Cash Flow | $12.2M | $7.8M | +57.10% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingCastle Biosciences, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“Our team delivered another strong quarter, reflecting consistent execution across our portfolio,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$35.75
Nov 4, 2026
Close after
$32.52
Nov 6, 2026
Move
-9.03%
981.9K shares traded, against a normal 370.28K
What Castle Biosciences, Inc. does
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes. We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn , Instagram, Facebook and X . DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Castle Biosciences, Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
